Expanded modes of administration with novel therapeutics for hemophilia. Hemophilia therapeutics have traditionally been limited to IV delivery, but new technologies have expanded to allow additional modes of administration. Subcutaneous injection of bioengineered clotting factors (N8-GP, BIVV002, CB2679d), as well as novel nonfactor therapeutics, may reduce the treatment burden, particularly in those patients with difficult IV access. Oral administration (CTB-FIX and pH-responsive anionic complexation hydrogels) would provide a noninvasive option, improving ease of administration, as well as patient compliance.